Tab (film-coated) 300 mg, 6x 10tablets
Mechanism of Action
Tenofovirdiphosphate inhibits the activity of HIV-1 reverse transcriptase and HBV polymerase by competing with the natural substrate deoxyadenosine 5′-triphosphate and, after incorporation into DNA, by DNA chain termination.
Tenovir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. The following points should be considered when initiating therapy with Tenovir for the treatment of HIV-1 infection: Tenovir should not be used in combination with (Tenofovir 300mg + Emtricitabine 200mg) or ( Efavirenz+ Emtricitabine+Tenofovir )
Tenovir is indicated for the treatment of chronic hepatitis B in adults. The following points should be considered when initiating therapy with Tenovir for the treatment of HBV infection: This indication is based primarily on data from treatment of nucleoside-treatment-naïve subjects and a smaller number of subjects who had previously received lamivudine or adefovir. Subjects were adults with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease.
Dosage and Administration:
For the treatment of HIV-1 or chronic hepatitis B: The dose of Tenovir is 300 mg once daily taken orally, without regard to food.
Lactic Acidosis/Severe Hepatomegaly with Steatosis, Severe Acute Exacerbation of Hepatitis, Worsening Renal Impairment, Decreases in Bone Mineral Density & Immune Reconstitution Syndrome.